What is Chai Discovery?
Chai Discovery operates at the frontier of artificial intelligence, specifically targeting the complex interactions between biochemical molecules. By treating biology as an engineering discipline rather than a purely observational science, the company aims to predict and reprogram the fundamental building blocks of life. The organization is composed of elite talent from industry-leading firms such as OpenAI, Meta FAIR, and Google X, providing a robust technical foundation for its ambitious research agenda. Its market position is defined by its ability to bridge the gap between generative AI and life sciences, offering a transformative approach to drug discovery and synthetic biology.
How much funding has Chai Discovery raised?
Chai Discovery has raised a total of $630M across 4 funding rounds:
Seed
$30M
Series A
$70M
Series B
$130M
Series C
$400M
Seed (2024): $30M, investors not publicly disclosed
Series A (2025): $70M led by Yosemite, Thrive Capital, SV Angel, and Menlo Ventures
Series B (2025): $130M supported by Thrive Capital, General Catalyst, Menlo Ventures, and Oak HC/FT
Series C (2026): $400M featuring Kleiner Perkins, Thrive Capital, OpenAI, Yosemite, Battery Ventures, Glade Brook Capital, Baillie Gifford, Sapphire Ventures, Sequoia Capital, Oak HC/FT, Index Ventures, General Catalyst, Bain Capital Ventures, Avenir, Menlo Ventures, and BDT Capital Partners
Key Investors in Chai Discovery
Thrive Capital
Thrive Capital is an investment venture capital company that operates out of New York, primarily dealing in internet and software investments.
Menlo Ventures
Menlo Ventures is a Menlo Park-based venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software and frontier tech.
OpenAI
OpenAI is an artificial intelligence research and deployment company focused on developing advanced AI systems that are safe, reliable, and beneficial for humanity.
What's next for Chai Discovery?
With the infusion of capital from its latest funding round, Chai Discovery is poised to accelerate its operational scaling and deepen its research capabilities. The company is expected to focus on expanding its proprietary AI infrastructure to handle increasingly complex biochemical simulations. As it moves beyond the initial development phases, the strategic focus will likely shift toward commercial partnerships and the deployment of its predictive models in real-world clinical and industrial settings. The backing of major institutional investors suggests a long-term trajectory aimed at establishing a dominant platform in the burgeoning field of AI-driven biotechnology.
See full Chai Discovery company page
